To determine the relative effectiveness of moderate versus more aggressive lipid lowering,
and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass
graft atherosclerosis and preventing occlusion of saphenous grafts of patients with
saphenous vein coronary bypass grafts placed 1 to 11 years previously.
To determine whether warfarin or lovastatin alone or in combination retarded the progression
of atherosclerotic plaques in the carotid arteries of high risk individuals with
asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.
To conduct a pilot study to determine whether lowering elevated serum cholesterol levels
with 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors reduced mortality
due to the sequelae of atherosclerotic cardiovascular disease in older men and women.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.